Drug Profile
BXCL 904
Alternative Names: BXCL904Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator BioXcel Corporation
- Class Anti-inflammatories
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Globoid cell leukodystrophy
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Globoid-cell-leukodystrophy in USA
- 23 May 2017 Preclinical trials in Globoid cell leukodystrophy in USA before May 2017 (BioXcel pipeline, May 2017)